Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2021 | $12.00 | Buy | Maxim Group |
D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
In the news release, Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds, issued 17-Jun-2025 by Acurx Pharmaceuticals, Inc. over PR Newswire, we have been advised by the company of an update to the release that correctly states the reduced exercise price for the warrants being exercised. The complete, corrected release follows: Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infe
STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per
As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence through one month after EOTIn contrast, 2 of 14 (14%) patients treated with the standard of care, oral vancomycin, experienced recurrent infection within one month after EOTWhen Phase 2b results are combined with Phase 2a results, 25 of 25 (100%) ibezapolstat-treated patients with CDI who had CC at EOT remained recurrence-free through 1 month after EOT; additionally, all 5 Phase 2b ibezapolstat-treated patients observed for up to 3 months following CC experienced no recurrence of infectio
Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference
STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79
STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,
SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)